WO2009037542A3 - Spirocyclic compounds as stearoyl coa desaturase inhibitors - Google Patents

Spirocyclic compounds as stearoyl coa desaturase inhibitors Download PDF

Info

Publication number
WO2009037542A3
WO2009037542A3 PCT/IB2008/002358 IB2008002358W WO2009037542A3 WO 2009037542 A3 WO2009037542 A3 WO 2009037542A3 IB 2008002358 W IB2008002358 W IB 2008002358W WO 2009037542 A3 WO2009037542 A3 WO 2009037542A3
Authority
WO
WIPO (PCT)
Prior art keywords
coa desaturase
stearoyl coa
spirocyclic compounds
desaturase inhibitors
inhibitors
Prior art date
Application number
PCT/IB2008/002358
Other languages
French (fr)
Other versions
WO2009037542A2 (en
Inventor
Sachin Sundarlal Chaudhari
Abraham Thomas
Ganesh Bhausaheb Gudade
Ashok Kadam
Nisha Parag Patil
Neelima Khairatkar-Joshi
Daisy Manish Shah
Original Assignee
Glenmark Pharmaceuticals Sa
Sachin Sundarlal Chaudhari
Abraham Thomas
Ganesh Bhausaheb Gudade
Ashok Kadam
Nisha Parag Patil
Neelima Khairatkar-Joshi
Daisy Manish Shah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa, Sachin Sundarlal Chaudhari, Abraham Thomas, Ganesh Bhausaheb Gudade, Ashok Kadam, Nisha Parag Patil, Neelima Khairatkar-Joshi, Daisy Manish Shah filed Critical Glenmark Pharmaceuticals Sa
Publication of WO2009037542A2 publication Critical patent/WO2009037542A2/en
Publication of WO2009037542A3 publication Critical patent/WO2009037542A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCDl). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD).
PCT/IB2008/002358 2007-09-20 2008-09-11 Spirocyclic compounds as stearoyl coa desaturase inhibitors WO2009037542A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1842MU2007 2007-09-20
IN1842/MUM/2007 2007-09-20
US1532907P 2007-12-20 2007-12-20
US61/015,329 2007-12-20
IN669MU2008 2008-03-28
IN669/MUM/2008 2008-03-28

Publications (2)

Publication Number Publication Date
WO2009037542A2 WO2009037542A2 (en) 2009-03-26
WO2009037542A3 true WO2009037542A3 (en) 2009-05-22

Family

ID=40451421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002358 WO2009037542A2 (en) 2007-09-20 2008-09-11 Spirocyclic compounds as stearoyl coa desaturase inhibitors

Country Status (1)

Country Link
WO (1) WO2009037542A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010112520A1 (en) * 2009-04-01 2010-10-07 Novartis Ag Spiro derivatives for the modulation of stearoyl-coa desaturase
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
CN105968093B (en) * 2016-06-29 2018-09-28 郑州明泽医药科技有限公司 The preparation method of amber love song Ge Lieting
MX2019008124A (en) 2017-01-06 2019-12-05 Yumanity Therapeutics Inc Methods for the treatment of neurological disorders.
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092179A1 (en) * 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Spiro derivative, production process, and antioxidant
WO2005054234A2 (en) * 2003-09-08 2005-06-16 Wockhardt Limited Substituted piperidino phenyloxazolidinones having antimicriobial activity with improved in vivo efficacy
WO2006129826A1 (en) * 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20070117824A1 (en) * 2005-11-23 2007-05-24 Berk Scott C Spirocyclic compounds
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007136605A2 (en) * 2006-05-18 2007-11-29 Merck & Co., Inc. Aryl-fused spirocyclic compounds
WO2008056687A1 (en) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Novel spiropiperidine derivative
WO2008096746A1 (en) * 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited Spiro compound and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (en) 1968-05-31 1971-05-15 Sandoz Ag Process for the preparation of 2-bromo-a-ergocryptine
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JP2004515533A (en) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド Peptide YY and peptide YY agonist for treating metabolic disorders
WO2003027637A2 (en) 2001-09-24 2003-04-03 Oregon Health And Science University Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
WO2004010927A2 (en) 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (en) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
WO2005011654A2 (en) 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005011656A2 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
ES2377406T3 (en) 2003-07-30 2012-03-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
CA2533899C (en) 2003-07-30 2011-01-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
SG145699A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use as therapeutic agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092179A1 (en) * 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Spiro derivative, production process, and antioxidant
WO2005054234A2 (en) * 2003-09-08 2005-06-16 Wockhardt Limited Substituted piperidino phenyloxazolidinones having antimicriobial activity with improved in vivo efficacy
WO2006129826A1 (en) * 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
EP1892241A1 (en) * 2005-05-30 2008-02-27 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20070117824A1 (en) * 2005-11-23 2007-05-24 Berk Scott C Spirocyclic compounds
WO2007071023A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007136605A2 (en) * 2006-05-18 2007-11-29 Merck & Co., Inc. Aryl-fused spirocyclic compounds
WO2008056687A1 (en) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Novel spiropiperidine derivative
WO2008096746A1 (en) * 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited Spiro compound and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAMS M T ET AL: "In vivo suppression of stearyl CoA desaturase activity by griseofulvin: Evidence against the involvement of lipid peroxidation", TOXICOLOGY AND APPLIED PHARMACOLOGY, ACADEMIC PRESS, vol. 96, no. 3, 1 December 1988 (1988-12-01), pages 541 - 549, XP024885189, ISSN: 0041-008X, [retrieved on 19881201] *

Also Published As

Publication number Publication date
WO2009037542A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2008062276A3 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
TW200745003A (en) Novel compounds
WO2010045258A3 (en) Spirocyclic gpr40 modulators
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2007052023A3 (en) Novel compounds
TW200630336A (en) Novel compounds
TW200621690A (en) Novel compounds
TW200732296A (en) Novel compounds
WO2010033543A3 (en) Substituted benzamides as cannabinoid receptor ligands
WO2009118596A3 (en) Phthalimide derivatives as trpa1 modulators
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2010109334A3 (en) Thienopyrimidinedione derivatives as trpa1 modulators
WO2010071783A8 (en) Thiazoles as cannabinoid receptor ligands
CO6382157A2 (en) PIRAZINA COMPOUNDS AS PHOSPHODESTERASE INHIBITORS 10
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2010028338A3 (en) Novel compounds as cannabinoid receptor ligands
TWI371446B (en) Novel compounds, their preparation and use
MX2010007391A (en) Trpa1 antagonists.
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2010010435A3 (en) Fused oxazole and thiazole derivatives as trpms modulators
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807045

Country of ref document: EP

Kind code of ref document: A2